Statins. In Utero to Death and Everything In-Between. Bryce M Kayhart, PharmD, BCPS MFMER slide-1
|
|
- Erik Gilbert
- 6 years ago
- Views:
Transcription
1 Statins In Utero to Death and Everything In-Between Bryce M Kayhart, PharmD, BCPS 2017 MFMER slide-1
2 Disclosures I have no financial relationships related to the material of this presentation to disclose MFMER slide-2
3 A Brief History 2017 MFMER slide-3
4 Objectives 1. Review the evidence supporting the use of statins in primary and secondary prevention of cardiovascular disease. 2. Identify strategies to manage statin intolerance. 3. Review the evidence surrounding statin use in pregnancy and end-of-life MFMER slide-4
5 A Brief History Acetyl-CoA + Acetoacetyl-CoA Statins HMG-CoA Mevalonic acid Squalene Lanosterol Cholesterol 2017 MFMER slide-5
6 A Brief History Statins were almost simultaneously discovered by Japanese (Endo, et al) and British (Brown et al) researchers in the 1970s, though Endo was the first to note HMG-CoA reductase as their target. Mevastatin, the compound isolated by both teams, was studied in dogs and later abandoned due toxicity. Lovastatin, isolated from Aspergillus terreus by researchers at Merck, became the first statin available for public consumption in Tobert JA. Nature Reviews Drug Discovery MFMER slide-6
7 The First Trials Hyperlipidemia was linked with cardiovascular disease by the Framingham Cohort Study. In the 1980s, other lipid-lowering drugs (cholestyramine, gemfibrozil) had been shown to modestly improve cardiovascular outcomes in patients with hyperlipidemia. Statins were known to substantially reduce blood LDL levels, but their effect on cardiovascular disease outcomes was unproven. The 4S trial was the first large, randomized, prospective clinical trial evaluating the efficacy of a statin 2017 MFMER slide-7
8 4S - The Beginning of an Era 4,444 patients with established cardiovascular disease randomized to receive placebo or simvastatin (10-40 mg daily for target total cholesterol mg/dl). Patients were followed for a median of 5.4 years for the primary outcome, overall mortality. Mortality % of patients RR % CI RR % CI RR % CI Placebo Simvastatin 0 Coronary Cardiovascular Overall Scandinavian Simvastatin Survival Study Group. Lancet MFMER slide-8
9 Statins vs. Placebo 4S marked the beginning of a long string of large phase three and four clinical trials 4S HPS ALLIANCE CARDS JUPITER ASCOT-LLA Post-CABG WOSCOPS PROSPER CARE LIPID ASPEN AURORA AFCAPS LIPS GISSI-HF 4D ALERT MEGA ALLHAT-LLT GISSI-P Cholesterol Treatment Trialists Collaboration. Lancet MFMER slide-9
10 Secondary Prevention Statins clearly benefit patients with established cardiovascular disease compared with placebo Overall mortality OR 0.82 (95% CI ) Major coronary events OR 0.69 (95% CI ) The benefits of high intensity statin therapy are generally considered to outweigh risks. Naci H, et al. Eur J Prev Cardiol Cholesterol Treatment Trialists Collaboration. Lancet MFMER slide-10
11 Statins in the water? Regulatory bodies in three nations commissioned studies examining concentrations of pharmaceutical substances in public water sources. Compound Mean PECdw (mcg/l) MTD (mg) MOS Tetrahydrocannabinol Total NSAIDs ,737 Total Statins ,937 Methadone ,173 MTD = minimum therapeutic dose MOS = margin of safety Pharmaceuticals in Drinking Water. World Health Organization MFMER slide-11
12 Primary Prevention Unlike statin use in secondary prevention, the utility of statins in primary prevention of cardiovascular disease is controversial. Inconsistent mortality benefit Drug cost Adverse effects De-emphasis on lifestyle changes The current AHA guidelines utilize age, presence/absence of diabetes, and ASCVD risk score to determine whether patients qualify for statin treatment How accurate is the ASCVD risk calculator? 2017 MFMER slide-12
13 Primary Prevention The Multi-Ethnic Study of Atherosclerosis (MESA) found that the ASCVD risk calculator overestimated 10 year event rate by 86% in men and 78% in women. The number needed to treat in primary prevention studies ranges from forty to several hundred. Major point of controversy surrounding the 2013 guidelines recommendations DeFilippis AP, et al. Ann Intern Med MFMER slide-13
14 Primary Prevention Two Cochrane reviews, from 2011 and 2013, both support statin use in primary prevention of cardiovascular disease Although reductions in all-cause mortality, composite endpoints, and revascularizations were found with no excess of adverse events, there was evidence of selective reporting of outcomes, failure to report adverse events, and inclusion of people with cardiovascular disease Only limited evidence showed that primary prevention with statins may be cost effective and improve patient quality of life. Reductions in all-cause mortality, major vascular events, and revascularizations were found with no excess of adverse events among people without evidence of CVD treated with statins. Taylor F, et al. Cochrane Database Syst Rev Taylor F, et al. Cochrane Database Syst Rev MFMER slide-14
15 Questions # 1 Which of the following statements is true? 1. Statins lower the incidence of non-fatal MI, but do not reduce mortality in patients with cardiovascular disease. 2. The 2013 AHA guidelines recommend statins as secondary prevention of cardiovascular disease and as primary prevention in high risk individuals. 3. The risks of high intensity statin therapy are generally believed to outweigh the benefits in patients with established cardiovascular disease MFMER slide-15
16 Adverse Effects 2017 MFMER slide-16
17 Case (Diabetes) CJ is a 62 year old male recently discharged from the hospital after suffering an acute MI. He was discharged with several new prescriptions, one of which is atorvastatin. He says to you, I just heard on the news that this drug will make me diabetic. I m already at risk because my parents were diabetic. What should I do? 2017 MFMER slide-17
18 Diabetes Multiple post-hoc analyses of landmark statin trials have noted a possible correlation between statin use and new-onset diabetes JUPITER brought this issue to the forefront Jupiter Primary Endpoint Incident Diabetes Rosuvastatin Placebo Ridker, et al. N Engl J Med MFMER slide-18
19 Diabetes A meta-analysis of 13 trials determined that the relative risk increase of new diabetes diagnosis with statin therapy is 9% (OR 1.09, 95% CI ). NNH = 255 for four years Sattar N, et al. Lancet MFMER slide-19
20 Diabetes Not all statins appear to affect glucose metabolism similarly Pitavastatin and pravastatin appear to have neutral effects on new diabetes diagnoses and Hgb-A1c. Notably, these are the two statins metabolized independent of the CYP450 system Rajpathak SN, et al. Diabetes Care MFMER slide-20
21 Do Statins Worsen Pre-existing Diabetes? Author Statin N (statin) N (control ) HbA1c (statin) HbA1c (control Colhoun, et al Atorva Knopp, et al Atorva Neil, et al Atorva T2DM Neil, et al Atorva Behounek, et al. Prava Freed, et al Atorva Freed, et al Atorva DALI Atorva DALI Atorva Subtotal Tajima, et al. Prava T1DM Collins, et al. Simva Konduracka, et al Atorva Subtotal Overall 0.12 (95% CI ) Erqou, et al. Diabetolgia MFMER slide-21
22 Statins and Diabetes: Summary Most (but not all) statins have been implicated in impaired glucose metabolism. The effect size is small and the number of cardiovascular events prevented by statin use exceeds the number of incident diagnoses of diabetes. Patients who place considerable value on avoid diabetes may be offered pravastatin or pitavastatin. Note that neither are high intensity statins MFMER slide-22
23 CJ is back CJ comes to see you again. Good news, doc, I don t have diabetes yet. The bad news is that my entire body hurts MFMER slide-23
24 Statin Intolerance Statin intolerance is an umbrella term for a variety of symptoms and clinical syndromes associated with statin use. Approximately 30% of statin users will experience muscle symptoms while taking statins. Muscle symptoms typically appear within 6 weeks of starting a statin, but may also occur at any time during treatment. Stroes ES, et al. Eur Heart J MFMER slide-24
25 Statin Intolerance Myopathy - generic term for muscle disease Myalgia - muscle symptoms with normal creatine kinase Myositis - muscle symptoms with elevated creatine kinase Rhabdomyolysis - muscle symptoms with creatine kinase > 10x ULN and acute kidney injury 2017 MFMER slide-25
26 Statin Intolerance Who s at Risk? Patient Risk Factors Age > 75 Female Asian descent Low BMI Excess physical activity Alcohol abuse Renal and/or hepatic dysfunction Treatment Risk Factors Lipid-soluble statins Simvastatin Lovastatin Atorvastatin Fluvastatin Statin dose CYP3A4 Inhibitors Stroes ES, et al. Eur Heart J Mancini GB, et al. Can J Cardiol MFMER slide-26
27 Statin Intolerance Management Hold the statin for 4 weeks for patients with: Intolerable symptoms CK elevations > 3x ULN Check renal and hepatic function Thorough medication review to rule out drug interactions Mancini GB, et al. Can J Cardiol MFMER slide-27
28 Managing Statin-Induced Myopathy 50% of patients will tolerate a re-challenge of the same statin. For patients experiencing muscle symptoms with a lipid soluble statin, it is reasonable to rechallenge with a water soluble statin. Pravastatin, rosuvastatin Extended dosing Twice weekly rosuvastatin 10 mg has been shown to reduce LDL by 26% Similar to simvastatin 20 mg daily Mancini GB, et al. Can J Cardiol MFMER slide-28
29 Managing Statin-Induced Myopathy 50% of patients will tolerate a re-challenge of the same statin. For patients experiencing muscle symptoms with a lipid soluble statin, it is reasonable to rechallenge with a water soluble statin. Pravastatin, rosuvastatin Extended dosing Twice weekly rosuvastatin 10 mg has been shown to reduce LDL by 26% Similar to simvastatin 20 mg daily Mancini GB, et al. Can J Cardiol Gadaria M, et al. Am J Cardiol MFMER slide-29
30 Managing Statin-Induced Myopathy There is no evidence supporting the use of coenzyme Q-10 to treat or prevent statinassociated myopathy. As a rule, patients who experience rhabdomyolysis during statin treatment should have the statin discontinued and not rechallenged. Taylor BA, et al. Atherosclerosis Mancini GB, et al. Can J Cardiol MFMER slide-30
31 Questions # 2 Which of the following statements is true? 1. Patients who have experienced statinassociated myopathy should never be rechallenged with the same statin. 2. Routine CoQ-10 supplementation is recommended for patients experiencing muscle weakness while taking a statin. 3. Holding statin therapy for two weeks and introducing pravastatin is reasonable for a patient experiencing myalgia on simvastatin MFMER slide-31
32 Case CT is a 32 year old female admitted with chest pain. She has new ST-segment depression but troponins are negative. She is diagnosed with unstable angina Medications fexofenadine 60 mg daily PRN Total Cholesterol: 432 mg/dl LDL: 289 mg/dl TG: 407 mg/dl hcg: 288,000 miu/ml 2017 MFMER slide-32
33 Case: Pregnancy All statins have two things in common Reduce cholesterol Pregnancy category X Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on data from investigational marketing experience, and the risks involved in the use of the drug in pregnancy women clearly outweigh the benefit MFMER slide-33
34 Statins and Pregnancy FDA s X-rating is derived from two animal studies in rats and rabbits. Minsker, et al. Rats received mevinolin at daily doses of 800 mg/kg on days 6-17 of gestation. Fetal malformations occurred in 29% of litters and included: Vertebrae malformations Rib malformations Gastroschisis Teratogenicity was suppressed by supplementing mevalonic acid. Minster DH, et al. Teratology MFMER slide-34
35 Statins and Pregnancy Dostal, et al. Rats received daily doses of 0, 10 mg/kg, 100 mg/kg, or 300 mg/kg on days 6-15 of gestation. No maternal or developmental toxicity observed in rats receiving 10 mg/kg or 100 mg/kg. Treatment related deaths, decreases in maternal food consumption, post-implantation loss, and decreased fetal body weight occurred in rats receiving 300 mg/kg. Rabbits received daily doses of 0, 10 mg/kg, 50 mg/kg, or 100 mg/kg on days 6-18 of gestation. Marked maternal toxicity and spontaneous abortion was frequent at 50 and 100 mg/kg doses. Dostal LA, et al. Teratology MFMER slide-35
36 Statins and Pregnancy Inadvertent fetal exposure to statins is becoming more common. Study Design n Statin Exposure Manson, et al, 1996 Trimester Case series 136 Lovastatin or simvastatin 1 st trimester in 89% Outcomes 85% normal births, 4% congenital anomaly, 8% spontaneous abortion, 1% stillbirth, 2% other Edison, et al, 2004 Case series (reports submitted to FDA) 52 Lovastatin, simvastatin, atorvastatin, cerivastatin 1 st trimester 17% fetal malformation Taguchi, et al, 2008 Cohort 64 (with matched controls) Atorvastatin, simvastatin, pravastatin, rosuvastatin 1 st trimester No difference in rate of congenital abnormalities (2.2% vs 1.9%, p = 0.93). Birth weight lower in statin group MFMER slide-36
37 Bateman, et al. Investigators screened Medicaid-enrolled women aged who completed pregnancies. A total of 886,996 completed pregnancies were identified. Pregnancies associated with chromosomal abnormalities and those in which the mother used known teratogenic drugs were excluded. Lithium, antineoplastic agents, retinoids, thalidomide Using pharmacy records, 1152 pregnancies were linked to 1 st - trimester statin use. Primary outcome: presence of one or more congenital malformation(s) in the infant Bateman, et al. BMJ MFMER slide-37
38 Bateman, et al. Baseline Characteristics Characteristics Statins (n = 1152) No Statins (n = 885,844) Age (31.2%) 45,018 (5.1%) Pre-existing diabetes 520 (45.1%) 27,090 (3.1%) Hypertension 468 (40.6%) 44,248 (5.0%) Obesity 269 (23.4%) 47,003 (5.3%) Tobacco Use 127 (11.0%) (7.8%) Alcohol use 46 (4.0%) (2.6%) Antihypertensive use 619 (53.7%) 58,882 (6.7%) Bateman, et al. BMJ MFMER slide-38
39 Bateman, et al. Baseline Characteristics Propensity score matched cohort Characteristics Statins (n = 1109) No Statins (n = 3,327) Age (29.2%) 974 (29.2%) Pre-existing diabetes 477 (43.0%) 1313 (39.5%) Hypertension 436 (39.3%) 1268 (38.1%) Obesity 262 (23.6%) 766 (23.0%) Tobacco Use 125 (11.3%) 368 (11.1%) Alcohol use 44 (4.0%) 147 (4.4%) Antihypertensive use 576 (51.9%) 1684 (50.6%) Bateman, et al. BMJ MFMER slide-39
40 Bateman, et al. Baseline Characteristics Propensity score matched cohort Characteristics Statins (n = 1109) No Statins (n = 3,327) Age (29.2%) 974 (29.2%) Pre-existing diabetes 477 (43.0%) 1313 (39.5%) Hypertension 436 (39.3%) 1268 (38.1%) Obesity 262 (23.6%) 766 (23.0%) Tobacco Use 125 (11.3%) 368 (11.1%) Alcohol use 44 (4.0%) 147 (4.4%) Antihypertensive use 576 (51.9%) 1684 (50.6%) Bateman, et al. BMJ MFMER slide-40
41 Bateman, et al. Results Statin Use Congenital Malformations HR Diabetes Adjustment Propensity Score Stratified No Statins 31,416/885,844 Reference Reference Reference Statins 73/1, (95% CI ) 1.34 ( ) 1.07 ( ) CNS Malformations, HR 1.76 (95%CI ) Cardiac Malformations, HR 1.25 (95%CI ) Respiratory Malformations, HR 1.02 (95%CI ) Facial and lip Malformations, HR 1.58 (95%CI ) Gastrointestinal Malformations, HR 1.02 (95%CI ) Genitourinary Malformations, HR 0.29 (95%CI ) Musculoskeletal Malformations, HR 0.91 (95%CI ) Other Malformations, HR 0.65 (95%CI ) Bateman, et al. BMJ MFMER slide-41
42 Statins and Pregnancy - Summary Statins pregnancy X designation is based on animal data in which the subjects received doses many time higher than therapeutic doses used in humans. Observational data has been inconsistent at best, but the largest published to date suggests that statins are not teratogenic to the extent previously believed. Currently, there is not enough data to support statin use in pregnant women. Human studies evaluating pravastatin for prevention of preeclampsia in high-risk pregnant women are currently underway. Bateman, et al. BMJ Constantine MM, et al. Obstet Gynecol MFMER slide-42
43 Case (End of Life) 15 years later, CJ is now 77 years old. Unfortunately, he just received a terminal diagnosis and the rest of his life will be measured in months MFMER slide-43
44 Kutner et al. Kutner et al. randomized 381 patients on statins who had life expectancies of 1-12 months to either stop or continue statin therapy for 1 year. Characteristic Discontinue Continue Total P value Male, n (%) 98 (51.9) 112 (58.3) 210 (55.1) 0.20 Age, mean (SD) 74.4 (11.7) 73.5 (11.5) 74.1 (11.6) 0.29 History of CVD, n (%) 111 (58.7) 110 (57.3) 221 (58.0) 0.78 Malignancy, n (%) 84 (44.4) 102 (53.1) 186 (48.8) MFMER slide-44
45 Kutner et al MFMER slide-45
46 Kutner et al. Kutner et al. randomized 381 patients on statins who had life expectancies of 1-12 months to either stop or continue statin therapy for 1 year. Outcome Discontinue Continue P value 60 day mortality, n (%) 45 (23.8) 39 (20.3) 0.36 Median time to death, days Cardiovascular event, n (%) 13 (6.9) 11 (5.7) 0.64 McGill COL Score, mean AUC MFMER slide-46
47 End-Of-Life Average cost saving per patient in the statin discontinuation group was $3.37 per day and $716 over the study period. Discontinue statins in everyone with life expectancy less than one year? 2017 MFMER slide-47
48 End-Of-Life In addition to reducing adverse cardiovascular outcomes, statins have also been shown to: Improve ischemic pain in patients with angina Improve functional outcomes after ischemic stroke Delay the onset of Alzheimer s dementia in at-risk patients Cannon CP, et al. N Engl J Med Marti-Fabregas J, et al. Stroke Wanamaker BL, et al. Clin Cardiol MFMER slide-48
49 End-Of-Life - Recommendations Primary Prevention Consider withdrawing statins from patients with life expectancy less than one year Secondary Prevention In patients with life expectancy of less than one year, consider continuing statins in those with ongoing chest pain or recent ischemic stroke. Consider discontinuing statins in patients with life expectancy less than one month or if you suspect adverse effects MFMER slide-49
50 Questions # 3 Which of the following statements is true? 1. Statins have been shown to prevent the onset of diabetes. 2. On average, statins can be expected to increase HbA1c by 2-3%. 3. Of the available statins, pravastatin is the most likely to cause or worsen diabetes. 4. None of the above are true MFMER slide-50
51 Questions # 4 Which of the following statements is true? 1. It is reasonable to discontinue primary preventative statin therapy in a 77 year old with a life expectancy of < 1 year. 2. The highest quality available evidence has failed to show teratogenicity of statin use during the first trimester. 3. Statins should be offered to pregnant women at high risk for cardiovascular events & 2 are true MFMER slide-51
52 Questions and Discussion 2017 MFMER slide-52
An example of a systematic review and meta-analysis
An example of a systematic review and meta-analysis Sattar N et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-742. Search strategy
More informationLAMIS (Livalo in AMI Study)
JCR 2018. 12. 8 LAMIS (Livalo in AMI Study) Young Joon Hong Division of Cardiology, Chonnam National University Hospital Gwangju, Korea Trend of hypercholesterolemia in Korea < Prevalence of hypercholesterolemia
More informationTreating Hyperlipidemias in Adults. Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC
Treating Hyperlipidemias in Adults Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC Disclosures Conflicts: None Talk will address off-label
More informationWeigh the benefit of statin treatment: LDL & Beyond
Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationCalculating RR, ARR, NNT
Calculating RR, ARR, NNT In a trial RR = Event rate (eg # of people with one stroke/ total people) in treatment group/event rate in the control group. ARR = Event rate in control group minus the event
More informationOriginal paper. Abstract. Abdullah S. Asia 1*, Al-Mahdi A. Modar 2, Hadi M. Ali 3
Original paper Frequency Of Potential Adverse Effects Of A Semisynthetic Statin (Simvastatin) Compared To A Synthetic Statin (Atorvastatin) Used To Reduce Cardiovascular Risk For Patients In Basra 1*,
More informationThe Clinical Debates
The Clinical Debates Speakers: Round 2: Statins for Primary Prevention of Cardiovascular Disease Matthew Cantrell, PharmD, BCPS, is a 2000 graduate of Mt. Mercy College and 2005 graduate from the University
More informationESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future
ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies
More informationStatins for Cardiovascular Disease Prevention in Women: Review of the Evidence
Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Karen E. Aspry, M.D., M.S., ABCL, FACC Assistant Professor of Medicine (Clinical) Alpert Medical School of Brown University
More informationAdvanced Treatment of LDL: How Low Should You Go?
Advanced Treatment of LDL: How Low Should You Go? C. Michael White, Pharm.D., FCP, FCCP Professor and Head, Pharmacy Practice, UCONN Co-Director, HOPE Collaborative Group, UCONN/Hartford Hospital Potential
More informationAdvanced Treatment of LDL: How Low Should You Go?
Advanced Treatment of LDL: How Low Should You Go? C. Michael White, Pharm.D., FCP, FCCP Professor and Head, Pharmacy Practice, UCONN Co-Director, HOPE Collaborative Group, UCONN/Hartford Hospital Potential
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationLipids What s new? Meera Jain, MD Providence Portland Medical Center
Lipids 2016- What s new? Meera Jain, MD Providence Portland Medical Center 1 Can I trust the ASCVD risk calculator? Do harms outweigh benefits in primary prevention? Is there anything besides a statin?
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationStatins in the elderly : Is there a rationale?
Statins in the elderly : Is there a rationale? Pr B Boland After a communication by Dr. Manfred Gogol EAMA, Sion, June, 2006 1 RCTs with Statins Meta-Analysis, 1999 182 abstracts or research papers 29
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationDrug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin
Drug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin Final Report Update 5 November 2009 This report reviews information about the comparative
More informationHow to Handle Statin Intolerance in the High Risk Patient
How to Handle Statin Intolerance in the High Risk Patient Thomas D. Conley, MD FACC FSCAI Disclosures: None 1 Definition of High Risk Primary Prevention ASCVD Risk Calculator Adults >21 yrs, LDL 190 mg/dl
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Cholesterol Treatment Trialists Collaboration.
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationStatins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review.
ISPUB.COM The Internet Journal of Cardiovascular Research Volume 7 Number 1 Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review. C ANYANWU, C NOSIRI Citation C ANYANWU, C NOSIRI.
More informationPharmacy Drug Class Review
Pharmacy Drug Class Review January 22, 2014 Authored By: Christina Manciocchi, Pharm.D. BCACP Disclaimer: Specific agents may have variations Edited By: Richard J. Kraft, Pharm.D.BCPS NEW CHOLESTEROL GUIDELINES
More informationTen Year Risk for CVD Event by Systolic HTN and CVD Risk Factors (Where s Age?)
Prevention and Treatment of CVD in Older Patients with Diabetes and Pre Diabetes: Hypertension and Dyslipidemia ASP Workshop on Diabetes Mellitus and Cardiovascular Disease in Older Adults Pentagon City
More informationDoes High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?
Late Breaking Clinical Trial Session at AHA 2017 Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? The REAL-CAD Study in 13,054 Patients With Stable Coronary Artery Disease Takeshi
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationSupplementary Online Content
Supplementary Online Content Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationAPPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES
APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES Main systematic reviews secondary studies on the general effectiveness of statins in secondary cardiovascular prevention (search date: 2003-2006) NICE.
More informationUse of Statins in the Nursing Home Population. Objectives
Use of Statins in the Nursing Home Population Cari Levy, MD, PhD University of Colorado Health Sciences Center and the Rocky Mountain Regional Medical Center Objectives Discuss the evidence base for use
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 8 Last Review Date: December 2, 2016 Repatha Description Repatha (evolocumab)
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationConflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines
Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy
More informationConflicts of interest. What's the Skinny on the Lipid Guidelines? Key Differences. Are you applying the new ACC/AHA Lipid guidelines in your practice?
Conflicts of interest What's the Skinny on the Lipid Guidelines? The presenter has no relevant conflicts of interest to disclose. Kathleen Vest, PharmD, CDE, BCACP At the end of this presentation, pharmacist
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More informationREAL-CAD. : Cardiovascular benefit of pitavastatin in stable coronary artery disease
REAL-CAD : Cardiovascular benefit of pitavastatin in stable coronary artery disease Soo-Joong Kim M.D., PhD. Department of Cardiology, Internal Medicine, Kyung Hee University Hospital I have nothing to
More informationCholesterol targets and therapy Thomas C. Andrews, MD, FACC
Cholesterol targets and therapy Thomas C. Andrews, MD, FACC 2 Statins in secondary prevention Still first line therapy! First line therapy: high intensity statin Dose individualized based on baseline LDL
More informationManagement of Post-transplant hyperlipidemia
Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and
More informationStudy 2 ( ) Pivotal Phase 3 Study Top-Line Results. October 29, 2018
Study 2 (1002-047) Pivotal Phase 3 Study Top-Line Results October 29, 2018 Safe Harbor Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements
More informationIn-Ho Chae. Seoul National University College of Medicine
The Earlier, The Better: Quantum Progress in ACS In-Ho Chae Seoul National University College of Medicine Quantum Leap in Statin Landmark Trials in ACS patients Randomized Controlled Studies of Lipid-Lowering
More informationThe Efficacy and Safety of Statins in the Primary Prevention of Cardiovascular Disease
University of North Dakota UND Scholarly Commons Physician Assistant Scholarly Project Papers Department of Physician Studies 2018 The Efficacy and Safety of Statins in the Primary Prevention of Cardiovascular
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationDrugs to Treat Type 2 DM Demonstrate Reductions in Major Adverse Cardiovascular Events
Drugs to Treat Type 2 DM Demonstrate Reductions in Major Adverse Cardiovascular Events How does all this play out when it comes to treating patients with type 2 DM who have chronic kidney disease? Therapeutic
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationStatin intolerance. Pr Franck Boccara, MD, PhD Cardiologie, INSERM UMRS938 CHU St Antoine, UPMC, Paris, France
Statin intolerance Pr Franck Boccara, MD, PhD Cardiologie, INSERM UMRS938 CHU St Antoine, UPMC, Paris, France Disclosure Statement of Financial Interest I currently have, or have had over the last two
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationDisclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?
Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl
More informationStudy 1 ( ) Pivotal Phase 3 Long-Term Safety Study Top-Line Results
Study 1 (1002-040) Pivotal Phase 3 Long-Term Safety Study Top-Line Results May 2, 2018 1 COPYRIGHT 2018 ESPERION. ALL RIGHTS RESERVED DO NOT COPY OR DISTRIBUTE Safe Harbor Forward-Looking Statements These
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationFEATURES OF THIS TALK
FEATURES OF THIS TALK OUTPATIENT MANAGEMENT OF CAD- A PRIMARY CARE PERSPECTIVE Michael G. Shlipak, MD, MPH Professor of Medicine, Biostatistics, and Epidemiology Chief, General Internal Medicine Covers
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationAccumulating Clinical data on PCSK9 Inhibition: Key Lessons and Challenges
ESC 2015 London Accumulating Clinical data on PCSK9 Inhibition: Key Lessons and Challenges Paul M Ridker, MD, MPH Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center for Cardiovascular
More informationDrug Class Review on HMG-CoA Reductase Inhibitors (Statins)
Drug Class Review on HMG-CoA Reductase Inhibitors () Final Report June 2004 Mark Helfand, MD, MPH Susan Carson, MPH Cathy Kelley, PharmD Oregon Evidence-based Practice Center Oregon Health & Science University
More informationModern Lipid Management:
Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)
More informationMaking War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.16.08 Subject: Repatha Page: 1 of 8 Last Review Date: September 18, 2015 Repatha Description Repatha
More informationCVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure
Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University
More informationDisclosures. Choosing a Statin/New Therapies. Case. How else would you do to treat him? LDL-C Reduction with Different Statin Strategies
Disclosures I have no disclosures relevant to this talk Choosing a Statin/New Therapies Aryan Aiyer, MD Assistant Professor of Medicine University of Pittsburgh School of Medicine UPMC Heart and Vascular
More informationFelix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study
Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Conflict of interest disclosure None Committee of Scientific Affairs Committee
More informationUpdate on Cholesterol Management: The 2013 ACC/AHA Guidelines
Update on Cholesterol Management: The 2013 ACC/AHA Guidelines Ola Akinboboye MD MPH MBA Medical Director, Queens Heart institute Rosedale. Associate Professor of Clinical Medicine, Weill Medical College
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More informationJAMA. 2011;305(24): Nora A. Kalagi, MSc
JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for
More informationThe All Wales Medicine Strategy Group (AWMSG) is asked to support implementation of the following prescribing indicators.
ENCLOSURE 5 APPENDIX 1 Paper presented to AWMSG in June 2006 AWPAG considered comments recorded in AWMSG minutes in July 2006 Paper subsequently updated and brought back to AWMSG for endorsement This paper
More informationStatin Intolerance. Jason Evanchan DO, FACC April 20 th, 2018
Statin Intolerance 2 nd Annual CV Course for Trainees and Early Career Physicians: Current Concepts in the Diagnosis and Management of Coronary Artery Disease Jason Evanchan DO, FACC April 20 th, 2018
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 9 Last Review Date: September 15, 2017 Repatha Description Repatha
More informationSupplementary Online Content
Supplementary Online Content Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic
More informationDyslipedemia New Guidelines
Dyslipedemia New Guidelines New ACC/AHA Prevention Guidelines on Blood Cholesterol November 12, 2013 Mohammed M Abd El Ghany Professor of Cardiology Cairo Universlty 1 1 0 Cholesterol Management Pharmacotherapy
More information7/27/2017 DISCLOSURES OUTPATIENT MANAGEMENT QUESTION #1 FEATURES OF THIS TALK OF CAD- A PRIMARY CARE PERSPECTIVE
DISCLOSURES OUTPATIENT MANAGEMENT OF CAD- A PRIMARY CARE PERSPECTIVE I am on the Scientific Advisory Boards with stock option compensation for the following companies: TAI Diagnostics Cricket Health, Inc.
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More informationCholesterol Treatment Update
Cholesterol Treatment Update Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public Health Disclosure:
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationUniv.-Doz. Prof. Dr. W. Renner
Pharmacogenetics of statin-inducedinduced myopathies Wilfried Renner Medical University Graz Clinical Institute of Medical and Chemical Laboratory Diagnostics It started with a fungus 1973: Isolation of
More informationNew Cholesterol Guidelines What the LDL are we supposed to do now?!
New Cholesterol Guidelines What the LDL are we supposed to do now?! Michael D. Shapiro Assistant Professor of Medicine and Radiology Knight Cardiovascular Institute Oregon Health & Science University 2013
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationA Mendelian Randomized Controlled Trial of Long Term Reduction in Low-Density Lipoprotein Cholesterol Beginning Early in Life
A Mendelian Randomized Controlled Trial of Long Term Reduction in Low-Density Lipoprotein Cholesterol Beginning Early in Life Brian A. Ference, M.D., M.Phil., M.Sc. ACC.12 Chicago 26 March 2012 Disclosures
More informationDrug Class Monograph
Drug Class Monograph Class: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Drugs: Praluent (alirocumab), Repatha (evolocumab) Line of Business: Medi-Cal Effective Date: February 17, 2016
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 9 Last Review Date: November 30, 2018 Repatha Description Repatha (evolocumab)
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships
More informationHyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH
Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the
More informationShould we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice
Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice Pathogenesis of atherosclerosis A decades-long disease course Inflammation Selectins ICAM IL M-CSF CRP
More informationReassessing the Benefits of Statins in the Prevention of Cardiovascular Disease in Diabetic Patients A Systematic Review and Meta-Analysis
Reprint from The Review of DIABETIC STUDIES Vol 10 No 2-3 2013 Special Issue CVD, Lipoproteins, and Diabetes The Review of DIABETIC STUDIES REVIEW Reassessing the Benefits of Statins in the Prevention
More informationLessons from Recent Atherosclerosis Trials
Lessons from Recent Atherosclerosis Trials Han, Ki Hoon MD PhD Asan Medical Center Seoul, Korea Change of concept Primary vs. secondary prevention Low risk vs. High risk High Risk CHD and equivalents CHD
More informationSTATINS FOR PAD Long - term prognosis
STATINS FOR PAD Long - term prognosis Prof. Pavel Poredos, MD, PhD Department of Vascular Disease University Medical Centre Ljubljana Slovenia DECLARATION OF CONFLICT OF INTEREST No conflict of interest
More informationTuesday, October 18 3:30 p.m. 5:30 p.m. Convention Center: Rooms 315 & 316
Ambulatory Care PRN Focus Session New Developments in Hypertension and Dyslipidemia Management Activity No. 0217-0000-11-101-L01-P (Application-Based Activity) Tuesday, October 18 3:30 p.m. 5:30 p.m. Convention
More informationStatin Treatment for Older Adults: The Impact of the 2013 ACC/AHA Cholesterol Guidelines
Drugs Aging (2015) 32:87 93 DOI 10.1007/s40266-014-0238-5 CURRENT OPINION Statin Treatment for Older Adults: The Impact of the 2013 ACC/AHA Cholesterol Guidelines Yitzchak Weinberger Benjamin H. Han Published
More informationThe statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient
Q J Med 2005; 98:599 614 Advance Access publication 8 July 2005 doi:10.1093/qjmed/hci093 Commentary The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient H.T. ONG
More informationSTATIN THERAPY IN THE ELDERLY: THERE ARE MILES TO GO BEFORE WE SLEEP
STATIN THERAPY IN THE ELDERLY: THERE ARE MILES TO GO BEFORE WE SLEEP Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA, FCCP, FAHA, FACC Director of Preventative Cardiology CGH Medical Center, Sterling, Illinois
More information2/23/2018. Management of Hyperlipidemia Update on Guidelines and Novel Therapies. Burden of Heart Disease in U.S.
Management of Hyperlipidemia Update on Guidelines and Novel Therapies SHARATH SUBRAMANIAN, MD, FACC February 24, 2018 Disclosures : None Burden of Heart Disease in U.S. https://www.cdc.gov/nchs/images/databriefs/251
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationNicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist
1 Nicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist New Cardiovascular Horizons Multidisciplinary Strategies for Optimal Cardiovascular Care February 7, 2015 2 Objectives After participating in
More information